A Phase I/II Trial of TKI258 (Dovitinib) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Inclusion Criteria:
- Female patients with breast cancer either in the primary or metastatic setting
- Tumor must be estrogen receptor and/or progesterone receptor positive and Her-2
negative
- Evidence of disease resistance to an aromatase inhibitor
- ECOG performance status 0 or 1
- Age 18 years or older
- Adequate laboratory values
- Able to give written informed consent
- Measurable disease
- No more than 2 prior chemotherapy regimens in the metastatic setting
- Unlimited prior hormonal therapy in the metastatic setting
- Life expectancy of greater than 3 months
- Post-menopausal
- Tumor must be available for central testing for FGFR1 amplification by FISH/CISH
Exclusion Criteria:
- Brain metastases
- Another primary malignancy within 3 years prior to starting drug therapy with the
exception of adequately treated in-site carcinoma of the uterine cervix or skin
cancer
- Chemotherapy within 3 weeks prior to starting study drug or not recovered from side
effects of previous therapy
- Administration of nitrosurea or mitomycin-C within 6 weeks prior to starting study
drug or not recovered from side effects of such therapy
- Administration of biologic therapy within 6 weeks prior to starting study drug or not
recovered from side effects of such therapy
- Radiotherapy within 4 weeks prior to starting study drug or 2 weeks in the case of
localized radiotherapy or not recovered from radiotherapy toxicities
- major surgery, open biopsy or significant traumatic injury within 4 weeks prior to
starting study drug or a minor procedure, percutaneous biopsy or placement of a
vascular access device within 1 week prior to starting study drug or not recovered
from side effects of such procedure or injury
- Chronic concomitant bisphosphonate therapy for the prevention of bone metastases.
Bisphosphonate/ denosumab therapy for the management of bone metastases or for the
treatment of osteoporosis s allowed.
- Impaired cardiac function or clinically significant cardiac disease
- Impairment of GI function or GI disease that may significantly alter the absorption
of dovitinib
- Cirrhosis, chronic active hepatitis, or chronic persistent hepatitis
- Known diagnosis of HIV infection
- Anticoagulation treatment with therapeutic doses of warfarin
- Any concurrent severe and/or uncontrolled concomitant medical condition that could
cause unacceptable safety risks or compromise compliance with the protocol
- Pregnant or breast-feeding
- Unwilling or unable to comply with the protocol